Ildikó Csóka

University of Szeged

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Examination of drug release from hydrogels

Polymers for Advanced Technologies (2003)

I. Erõs Ildikó Csóka Erzsébet Csányi Tünde Takács‐Wormsdorff

Abstract The liberation of several important active agents was studied from hydrogels produced from new macromolecular substances. Liberation was examined with an in vitro method, with a Hanson's vertical diffusion cell. Polymers were used in an increasing concentration, while the quantity of active agents was constant. Several quantitative relationships were established after the examination of liberation from 240 drug‐containing gels. A power function was found between the concentration of the polymers and the quantity of the liberated active agents, while a logarithmic relationship existed between the viscosity of the gels and the extent of liberation. Interactions between the active agent and the vehicles can be inferred from the rheological functions as well as from the constants of the liberation versus concentration and liberation versus viscosity functions. Copyright © 2003 John Wiley & Sons, Ltd.

Liberation

10.1002/pat.405

Cite

Citations (11)

Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach

Pharmaceutics (2020)

Gábor Katona György Tibor Balogh Gergő Dargó Róbert Gáspár Árpád Márki

The aim of this study was to optimize the formulation of meloxicam (MEL)-containing human serum albumin (HSA) nanoparticles for nose-to-brain via a quality by design (QbD) approach. Liquid and dried formulations of nanoparticles containing Tween 80 and without the surfactant were investigated. Various properties, such as the Z-average, zeta potential, encapsulation efficacy (EE), conjugation of MEL and HSA, physical stability, in vitro dissolution, in vitro permeability, and in vivo plasma and brain distribution of MEL were characterized. From a stability point of view, a solid product (Mel-HSA-Tween) is recommended for further development since it met the desired critical parameters (176 ± 0.3 nm Z-average, 0.205 ± 0.01 PdI, −14.1 ± 0.7 mV zeta potential) after 6 months of storage. In vitro examination showed a significantly increased drug dissolution and permeability of MEL-containing nanoparticles, especially in the case of applying Tween 80. The in vivo studies confirmed both the trans-epithelial and axonal transport of nanoparticles, and a significantly higher cerebral concentration of MEL was detected with nose-to-brain delivery, in comparison with intravenous or per os administration. These results indicate intranasal the administration of optimized MEL-containing HSA formulations as a potentially applicable “value-added” product for the treatment of neuroinflammation.

Zeta potential

Meloxicam

Human serum albumin

Critical quality attributes

Serum Albumin

10.3390/pharmaceutics12020097

Cite

Citations (45)

Development of Thermoresponsive-Gel-Matrix-Embedded Amoxicillin Trihydrate-Loaded Bovine Serum Albumin Nanoparticles for Local Intranasal Therapy

Gels (2022)

Sandra Aulia Mardikasari Mária Budai-Szűcs László Orosz Katalin Burián Ildikó Csóka

A high dose of amoxicillin is recommended as the first-line therapy for acute bacterial rhinosinusitis (ABR). However, oral administration of amoxicillin is connected to many adverse reactions coupled with moderate bioavailability (~60%). Therefore, this study aimed to develop a topical nasal preparation of amoxicillin, employing a thermoresponsive nanogel system to increase nasal residence time and prolong drug release. Rheological investigations revealed that formulations containing 21–23% w/w Poloxamer 407 (P407) were in accordance with the requirement of nasal administration (gelling temperature ~35 °C). The average hydrodynamic diameter (<200 nm), pH (6.7–6.9), and hypertonic osmolality (611–663 mOsmol/L) of the in situ gelling nasal nanogel appeared as suitable characteristics for local rhinosinusitis treatment. Moreover, taking into account the mucoadhesive strength and drug release studies, the 21% w/w P407 could be considered as an optimized concentration for effective nasal delivery. Antibacterial activity studies showed that the ability of amoxicillin-loaded in situ gelling nasal nanogel to inhibit bacterial growth (five common ABR pathogens) preserved its effectiveness in comparison to 1 mg/mL amoxicillin aqueous solution as a positive control. Altogether, the developed amoxicillin-loaded in situ gelling thermoresponsive nasal nanogel can be a potential candidate for local antibiotic therapy in the nasal cavity.

Bovine serum albumin

Matrix (chemical analysis)

10.3390/gels8110750

Cite

Citations (9)

Modelling urinary catheters with innovative approaches for patient’s using QbD & 3D bioprinting

S. P. Yamini Kanti Ildikó Csóka Lívia Adalbert Orsolya Jójárt-Laczkovich

Catheters have been widely used over forty years by patients who have been unable to empty their bladders in a natural way is to use Catheters.But, using catheters comes up with many complications such as painful and traumatizing process, causing injuries and can also cause different types of Urinary Tract Infections.

3D bioprinting

10.14232/syrptbrs.2022.38

Cite

Citations (0)

Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes

Drug Discovery Today (2018)

Ildikó Csóka Edina Pallagi T Paál

Quality by Design

Critical quality attributes

10.1016/j.drudis.2018.03.012

Cite

Citations (45)

Development of Lomustine and n-Propyl Gallate Co-Encapsulated Liposomes for Targeting Glioblastoma Multiforme via Intranasal Administration

Pharmaceutics (2022)

Gábor Katona Fakhara Sabir Bence Sipos Muhammad Naveed Zsuzsanna Schelz

This work aimed to develop lomustine (LOM) and n-propyl gallate (PG)-loaded liposomes suitable for targeting glioblastoma multiforme (GBM) via the auspicious nose-to-brain drug delivery pathway. The therapeutical effect of LOM, as a nitrosourea compound, can be potentiated by PG suitable for enhanced anti-cancer therapy. Nose-to-brain delivery of PG and LOM combined in liposomes can overcome the poor water solubility, absorption properties, and toxicity issues in the systemic circulation. Optimization and characterization of the liposomal carrier with binary drug contents were carried out in order to achieve adequate encapsulation efficiency, loading capacity, drug release, and ex vivo permeation. The optimized liposome co-encapsulated with both drugs showed suitable Z-average (127 ± 6.9 nm), size distribution (polydispersity index of 0.142 ± 0.009), zeta potential (-34 ± 1.7 mV), and high encapsulation efficacy (63.57 ± 1.3% of PG and 73.45 ± 2.2% of LOM, respectively) meeting the acceptance criteria of nose-to-brain transport for both drugs. MTT assays of PG-LOM formulations were also conducted on NIH/3T3 (murine embryonic fibroblast), U87 (glioblastoma), and A2780 (ovarian cancer) cell lines indicating reduced an antiproliferative effect on all types of cells. Our results supported the use of this novel combination of LOM and PG in a liposomal formulation as a promising carrier for glioblastoma targeting via the intranasal route.

Lomustine

Nitrosourea

10.3390/pharmaceutics14030631

Cite

Citations (19)

Development of a combined nanosystem as a dry powder inhaler for the treatment of pulmonary inflammations

Heba Banat Ildikó Csóka Rita Ambrus

Dry-powder inhaler

10.14232/syrptbrs.2023.33

Cite

Citations (0)

Coherent emulsions containing alkylpolyglucoside esters as emulsifiers

Springer eBooks (2004)

Magdolna Kónya P. Bohus Laura Paglino Ildikó Csóka Erzsébet Csányi

Fatty alcohol

10.1007/978-3-540-45119-8_27

Cite

Citations (4)

Soluplus® promotes efficient transport of meloxicam to the central nervous system via nasal administration

International Journal of Pharmaceutics (2023)

Bence Sipos Zsolt Bella Ilona Gróf Szilvia Veszelka Mária A. Deli

Mucoadhesion

Meloxicam

Nanocarriers

Ex vivo

10.1016/j.ijpharm.2023.122594

Cite

Citations (12)

A comparison study of lipid and polymeric nanoparticles in the nasal delivery of meloxicam: Formulation, characterization, and in vitro evaluation

International Journal of Pharmaceutics (2021)

Hussein Akel Ruba Ismail Gábor Katona Fakhara Sabir Rita Ambrus

With the increasingly widespread of central nervous system (CNS) disorders and the lack of sufficiently effective medication, meloxicam (MEL) has been reported as a possible medication for Alzheimer's disease (AD) management. Unfortunately, following the conventional application routes, the low brain bioavailability of MEL forms a significant limitation. The intranasal (IN) administration route is considered revolutionary for CNS medications delivery. The objective of the present study was to develop two types of nanocarriers, poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) and solid lipid nanoparticles (SLNs), for the IN delivery of MEL adapting the Quality by Design approach (QbD). Turning then to further enhance the optimized nanoformulation behavior by chitosan-coating. SLNs showed higher encapsulation efficacy (EE) and drug loading (DL) than PLGA NPs 87.26% (EE) and 2.67% (DL); 72.23% (EE) and 2.55% (DL), respectively. MEL encapsulated into the nanoformulations improved in vitro release, mucoadhesion, and permeation behavior compared to the native drug with greater superiority of chitosan-coated SLNs (C-SLNs). In vitro-in vivo correlation (IVIVC) results estimated a significant in vivo brain distribution of the nanoformulations compared to native MEL with estimated greater potential in the C-SLNs. Hence, MEL encapsulation into C-SLNs towards IN route can be promising in enhancing its brain bioavailability.

Solid lipid nanoparticle

PLGA

Nanocarriers

Meloxicam

Mucoadhesion

10.1016/j.ijpharm.2021.120724

Cite

Citations (44)